Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Pocock

Showing results (41-50 of 245) with videos related to

Pageof 25
Sort By:
Journal of Cardiovascular Translational Research|January 9, 2021
Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary SyndromesRoberto Martín-Asenjo, John Gregson, Xavier Rossello, et al.
Journal of Hypertension|January 16, 2002
Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groupsJerzy Gasowski, Robert H Fagard, Jan A Staessen, et al.
BMC Medicine|July 17, 2018
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research DatalinkJohn Wilding, Thomas Godec, Kamlesh Khunti, et al.
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Experience collecting interim data on mortality: an example from the RALES studyJanet Wittes, Jolie Palensky, Debra Asner, et al.
European Heart Journal. Acute Cardiovascular Care|October 11, 2014
Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) studyStuart Pocock, Héctor Bueno, Muriel Licour, et al.
Circulation. Heart Failure|April 30, 2013
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF studyHenry Krum, Harry Shi, Bertram Pitt, et al.
Clinical Trials (London, England)|November 11, 2005
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paperKay Dickersin, Barry R Davis, Dennis O Dixon, et al.
Journal of the American Heart Association|March 21, 2025
Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve ReplacementRan Liu, Yang Li, Lihua Zhang, et al.
JACC. Heart Failure|November 30, 2019
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCATJoão Pedro Ferreira, Xavier Rossello, Romain Eschalier, et al.
JACC. Heart Failure|January 6, 2026
Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-PreservedJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
Pageof 25

Showing results (41-50 of 245) with videos related to

Sort By:
Pageof 25
Journal of Cardiovascular Translational Research|January 9, 2021
Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary SyndromesRoberto Martín-Asenjo, John Gregson, Xavier Rossello, et al.
Journal of Hypertension|January 16, 2002
Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groupsJerzy Gasowski, Robert H Fagard, Jan A Staessen, et al.
BMC Medicine|July 17, 2018
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research DatalinkJohn Wilding, Thomas Godec, Kamlesh Khunti, et al.
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Experience collecting interim data on mortality: an example from the RALES studyJanet Wittes, Jolie Palensky, Debra Asner, et al.
European Heart Journal. Acute Cardiovascular Care|October 11, 2014
Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) studyStuart Pocock, Héctor Bueno, Muriel Licour, et al.
Circulation. Heart Failure|April 30, 2013
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF studyHenry Krum, Harry Shi, Bertram Pitt, et al.
Clinical Trials (London, England)|November 11, 2005
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paperKay Dickersin, Barry R Davis, Dennis O Dixon, et al.
Journal of the American Heart Association|March 21, 2025
Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve ReplacementRan Liu, Yang Li, Lihua Zhang, et al.
JACC. Heart Failure|November 30, 2019
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCATJoão Pedro Ferreira, Xavier Rossello, Romain Eschalier, et al.
JACC. Heart Failure|January 6, 2026
Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-PreservedJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
Pageof 25